OBI Pharma

OBI Pharma is a biopharmaceutical company that specializes in new drug research with a primary focus on addressing unmet medical needs in challenging diseases, particularly cancer. The company aims to enhance health and quality of life through the development of cost-effective therapeutics. OBI Pharma operates through four key segments: anti-cancer new drugs, bispecific monoclonal antibodies, botulinum toxin new drugs, and contract development and manufacturing (CDMO). By concentrating on innovative treatment solutions, OBI Pharma is committed to advancing healthcare outcomes globally. The company was sold to Eusa Pharma in 2018, marking a significant transition in its business trajectory.